Big Rock Partners Acquisition announced today that it has entered into a merger agreement with NeuroRx, a clinical stage, small molecule pharmaceutical company. The combined company would have an estimated equity value greater than $500 million.
NeuroRx develops novel therapeutics for the treatment of COVID-19 and Bipolar Depression.
Terms of the deal call for NeuroRX shareholder to receive as much as $350 million in additional stock and cash if the company meets certain thresholds, including FDA approval of the company’s COVID and antidepressant drugs.
The combined company is expected to continue trading on the Nasdaq under “NRXP.” The transaction is expected to occur in the first or second quarter of 2021. Read more.
